Ketamine for Methamphetamine Use Disorder
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-65
SponsorUniversity of Texas Southwestern Medical Center
About this trial
This study aims to determine whether treatment response with IV ketamine is superior to treatment response with IV midazolam in adults with moderate to severe MUD.
The study design is a 12-week randomized, double-blind, controlled trial comparing intravenous (IV) ketamine against IV midazolam, delivered over six weeks in 120 adults with moderate to severe methamphetamine use disorder (MUD).
Eligibility criteria
Qualifiers
Be 18 to 65 years old
Be able to sufficiently understand, speak, and read English
Be interested in reducing or stopping methamphetamine use
Meet criteria for methamphetamine use disorder
Disqualifiers
Have been in a research study of pharmacological or behavioral treatment for addiction within 6 months prior to written informed consent
Be currently in jail, prison, or inpatient overnight facility as required by court of law
Have upcoming surgery planned or scheduled
Be currently pregnant, breastfeeding, or planning on conception, if biologically female
Trial design
Treatments tested in this trial
- Ketamine Hydrochloride
- Midazolam Hydrochloride
Treatment groups
120 Participants
are divided into 2 treatment groupsLocations
5Alameda Health System94578, San LeandroCalifornia, United States
Interdisciplinary Substance Use and Brain Injury Facility87106, AlbuquerqueNew Mexico, United States
Addiction Institute of Mount Sinai10029, New YorkNew York, United States
Prisma Health29617, GreenvilleSouth Carolina, United States
Sponsors and collaborators
University of Texas Southwestern Medical Center
Lead sponsor
Source ClinicalTrials.gov